Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

Progress on Coagulin-B hemophilia B gene therapy reported at Hematology meeting

Dec. 5, 2000

R-102444, a prodrug-type 5-HT2 antagonist, as a promising candidate for thrombosis

Nov. 30, 2000

Anticoagulants targeting thrombin developed at ADIR

Nov. 29, 2000

Potent new antiplatelet agent synthesized at Welfide acts as 5-HT2 receptor antagonist

Nov. 28, 2000

Merck's new integrin receptor antagonists for thrombosis, osteoporosis, atherosclerosis

Nov. 24, 2000

Avigen and Bayer collaborate to bring Coagulin-B to market

Nov. 24, 2000

ACUTE II results presented at AHA sessions

Nov. 23, 2000

Baxter's new recombinant hemophilia therapy enters phase III

Nov. 23, 2000

FDA approves Lovenox for seventh indication

Nov. 22, 2000

S-18886 improves endothelial function in CAD patients

Nov. 21, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...